Back

Supporting Early Stage Neuroscience Research and Development in Asia

Request Number N835353
Author
Need details
Description

Worldwide R&D organization is interested in establishing research collaborations with Asian researchers and biotechnology companies working in the field of Neuroscience. Pfizer wishes to establish and progress early stage research collaborations to develop therapeutics, expand the understanding of disease biology and identify biomarkers that impact neurodegenerative and neurological diseases including:

    • Alzheimer's Disease (AD)
    • Parkinson's Disease (PD)
    • Huntington's Disease
    • Cerebrovascular Disease.

 

Key Success Criteria

    • Proposals must address one or more of Pfizer's areas of interest (outlined in Possible Approach section)
    • Proposals must have specific and defined milestones that can be reasonably met within a two year time period
    • Program supported by in vitro or in vivo data derived from disease relevant models that are thought to be predictive of clinical conditions and outcomes.
    • Research and development must be undertaken by academic groups or biotechnology companies whose primary place of business within Asia.

 

Background

Neurological and psychiatric disorders are a leading cause of disability. To meet these patient needs, Pfizer is taking a bold leadership approach that spans symptomatic to disease-modifying therapies. As a result, Pfizer is investigating new ways to attack Alzheimer’s Disease, Parkinson's Disease, Schizophrenia and other debilitating conditions of the nervous system. Pfizer's neuroscientists are eager to work with world-class partners and collaborators who share our mission to improve the lives of patients suffering from neurological and psychiatric disorders.

 

Possible Approaches of Interest

Pfizer is specifically interested in supporting projects focused upon:

    • Novel potential symptomatic agents for AD or PD (could include L-DOPA-induced dyskinesias)
    • Agents affecting microvascular circulation and brain metabolism with validated link to AD
    • Imaging agents (e.g., tau, synuclein neurotransmitters, neuroinflammation and gliosis)
    • Translational biomarkers – preclinical to clinical
    • Biological samples (e.g., induced pluripotent stem cells) from well defined AD or PD patient populations
    • Agents impacting neuroinflammation
    • Conformational antibodies that have cross reactivity to all "amyloids" (eg tau, AB, huntingtin, d-synuclein)
    • Novel delivery of growth factors and other biotherapeutics (e.g., viral delivery or implanted device)

 

Areas of No Interest

Pfizer is NOT seeking proposals related to:

    • Protein 'anti-aggregator"
    • 'Black box' mechanisms
    • Anti-oxidants
    • Aß lowering agents (small molecules in phase 1, or later, clinical studies may be of interest)
    • Large molecule therapeutics with CNS targets without data for brain penetration
    • Proposals for block funding collaborations that do not have specific and defined milestones that can be reasonably be met within a two year time period.
    • Proposals that are defined and driven from academic groups or biotechnology companies whose primary place of business falls outside Asia.

 

Preferred Collaboration Type

Pfizer seeks to establish truly collaborative relationships that bring a high level of interaction between our R&D groups and appropriate partner organizations.

 

For appropriate opportunities, Pfizer may provide access to many of their key drug discovery and development resources.

 

Pfizer is particularly interested in partnering opportunities with universities, research institutes or biotechnology companies that reside in China, Hong Kong, Japan, Korean, Taiwan, Singapore or India. Proposals will be assessed upon how well they address the specific partnering needs detailed above, the likelihood of meeting key milestones within a two year period, and upon the track record of the Principle Investigators as demonstrated by a publication record and success in attracting competitive funding.

 

How to Respond:

We are looking for a completed Response Template, which may contain a concise abstract/executive summary. The proposal should briefly describe the technical approach and provide information on technology performance, background and description of the responding team and their related experience. To Respond, please use the red Respond Now button located to the right. Please note that only non-confidential information can be accepted.

 

By submitting a response you represent that the response does not contain and will not be deemed to contain any confidential information of any kind whatsoever. All Personal Information disclosed to Pfizer within a response will be utilized in accord with principles and polices as described at http://www.pfizer.com/general/privacy. By submitting a response, you also acknowledge and confirm that you have consulted with your Technology Transfer Office, Business Development Office or any other required group and that you have their approval to submit the response. By submitting a response, you acknowledge that the Need's sponsoring organization, in its sole discretion, may select or reject a response or any portion thereof.

 

Your NineSights community profile should contain all required information in order to provide us with appropriate contact information for your responses. For questions about NineSights privacy and security, please feel free to post in our forums.

Background
Migrated from previous NineSights Community Site
Key Success Criteria
Migrated from previous NineSights Community Site
Preferred Collaboration types
  • To Be Negotiated
Point of Contact
Darren Coomber
Area of Interest
  • Chemical Manufacturing
  • Family & Consumer Products & Services
  • Financial Services
  • Food & Beverage
  • Manufacturing & Fabrication
  • Medical Products & Services
  • Packaging
  • Professional Services
  • Other
Organization
Pfizer
Due Date
April 11, 2014
Award Amount
TBD
Attachments
This page does not have file attachments.
This page does not have file attachments.
Comments